Novel controlled-release polylactic-co-glycolic acid (PLGA) nanoparticles for sodium thiosulphate, a hydrogen sulphide donor, retains pro-angiogenic potential of hydrogen sulphide

Hydrogen sulphide (H2S) is an endogenous gaseous signalling molecule observing cardioprotective qualities in various experimental models. However, its therapeutic application limited due to rapid release vivo and potential toxicity. Controlled-release nanoparticles (NPs), such as polylactic-co-glycolic acid (PLGA) NPs entrapping H2S compounds may address these issues. PLGA NPs’ encapsulating sodium thiosulphate (STS), a donor, were prepared by emulsification sonication-solvent evaporation polyvinyl alcohol (PVA). Sonication time was varied between 15 45 s PVA concentration 0.3 0.7% w/v. characterised, cellular uptake, generation encapsulated STS angiogenic explored. An increase sonication well decreased size resulting kinetics uptake over 24 h. Encapsulated gave controlled of h whereas non-encapsulated peaked at 2 Finally, we observed entrapped maintained pro-angiogenic potential. are promising controlled-release delivery system with offer sustained levels. Results this study demonstrate formulation STS-loaded provides therefore H2S. internalised into cells critically, able maintain the